Exelixis Inc Increase (Decrease) in Contract with Customer, Liability
Exelixis Inc (EXEL) reported Increase (Decrease) in Contract with Customer, Liability of -$3.14 million for the 12-month period ending 2023-12-29, per its 10-K filed 2024-02-06.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2024-02-06
- Exelixis Inc increase (decrease) in contract with customer, liability for the quarter ending 2023-06-30 was $162.00K.
- Exelixis Inc increase (decrease) in contract with customer, liability for the quarter ending 2023-03-31 was -$707.00K.
- Exelixis Inc increase (decrease) in contract with customer, liability for the quarter ending 2022-12-30 was $647.00K.
- Exelixis Inc increase (decrease) in contract with customer, liability for the quarter ending 2022-09-30 was -$1.30M, a 162.21% decline year-over-year.
- Exelixis Inc increase (decrease) in contract with customer, liability for fiscal 2023 was -$3.14M.
- Exelixis Inc increase (decrease) in contract with customer, liability for fiscal 2022 was -$2.48M, a 122.56% decline from fiscal 2021.
- Exelixis Inc increase (decrease) in contract with customer, liability for fiscal 2021 was $11.01M.
- Exelixis Inc increase (decrease) in contract with customer, liability for fiscal 2021 was -$1.05M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2023-12-29 | -$3.14M 10-K · filed 2024-02-06 | |||
| 2023-06-30 | $162.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | -$545.00K 10-Q · filed 2023-08-01 | $102.00K derived: sum of 3 quarters · filed 2024-02-06 | -$1.20M derived: sum of 4 quarters · filed 2024-02-06 |
| 2023-03-31 | -$707.00K 10-Q · filed 2023-05-09 | -$60.00K derived: sum of 2 quarters · filed 2024-02-06 | -$1.36M derived: sum of 3 quarters · filed 2024-02-06 | -$2.02M derived: sum of 4 quarters · filed 2024-02-06 |
| 2022-12-30 | $647.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-06 | -$652.00K derived: sum of 2 quarters · filed 2024-02-06 | -$1.31M derived: sum of 3 quarters · filed 2024-02-06 | -$2.48M 10-K · filed 2024-02-06 |
| 2022-09-30 | -$1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | -$1.96M derived: sum of 2 quarters · filed 2023-08-01 | -$3.13M 10-Q · filed 2022-11-01 | -$3.56M derived: sum of 4 quarters · filed 2024-02-06 |
| 2022-07-01 | -$662.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-01 | -$1.83M 10-Q · filed 2023-08-01 | -$2.26M derived: sum of 3 quarters · filed 2024-02-06 | -$169.00K derived: sum of 4 quarters · filed 2024-02-06 |
| 2022-04-01 | -$1.17M 10-Q · filed 2023-05-09 | -$1.59M derived: sum of 2 quarters · filed 2024-02-06 | $493.00K derived: sum of 3 quarters · filed 2024-02-06 | -$3.58M derived: sum of 4 quarters · filed 2024-02-06 |
| 2021-12-31 | -$426.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-06 | $1.66M derived: sum of 2 quarters · filed 2024-02-06 | -$2.41M derived: sum of 3 quarters · filed 2024-02-06 | $11.01M 10-K · filed 2024-02-06 |
| 2021-10-01 | $2.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | -$1.99M derived: sum of 2 quarters · filed 2022-11-01 | $11.43M 10-Q · filed 2022-11-01 | $6.37M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-07-02 | -$4.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $9.35M 10-Q · filed 2022-08-09 | $4.28M derived: sum of 3 quarters · filed 2023-02-07 | -$1.36M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-04-02 | $13.42M 10-Q · filed 2022-05-10 | $8.36M derived: sum of 2 quarters · filed 2023-02-07 | $2.71M derived: sum of 3 quarters · filed 2023-02-07 | $3.52M derived: sum of 4 quarters · filed 2023-02-07 |
| 2021-01-01 | -$5.06M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-07 | -$10.71M derived: sum of 2 quarters · filed 2023-02-07 | -$9.90M derived: sum of 3 quarters · filed 2023-02-07 | -$1.05M 10-K · filed 2023-02-07 |
| 2020-10-02 | -$5.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | -$4.84M derived: sum of 2 quarters · filed 2021-11-02 | $4.01M 10-Q · filed 2021-11-02 | -$8.88M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-07-03 | $809.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $9.66M 10-Q · filed 2021-08-05 | -$3.23M derived: sum of 3 quarters · filed 2022-02-18 | -$4.30M derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-04-03 | $8.85M 10-Q · filed 2021-05-06 | -$4.04M derived: sum of 2 quarters · filed 2022-02-18 | -$5.11M derived: sum of 3 quarters · filed 2022-02-18 | $862.00K derived: sum of 4 quarters · filed 2022-02-18 |
| 2020-01-03 | -$12.89M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | -$13.96M derived: sum of 2 quarters · filed 2022-02-18 | -$7.99M derived: sum of 3 quarters · filed 2022-02-18 | -$9.30M 10-K · filed 2022-02-18 |
| 2019-09-27 | -$1.06M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $4.91M derived: sum of 2 quarters · filed 2020-11-05 | $3.59M 10-Q · filed 2020-11-05 | $5.41M derived: sum of 4 quarters · filed 2020-11-05 |
| 2019-06-28 | $5.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $4.66M 10-Q · filed 2020-08-06 | $6.47M derived: sum of 3 quarters · filed 2020-08-06 | -$983.00K derived: sum of 4 quarters · filed 2020-08-06 |
| 2019-03-29 | -$1.31M 10-Q · filed 2020-05-05 | $506.00K derived: sum of 2 quarters · filed 2020-05-05 | -$6.95M derived: sum of 3 quarters · filed 2020-05-05 | $1.61M derived: sum of 4 quarters · filed 2020-05-05 |
| 2018-12-28 | $1.82M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | -$5.64M derived: sum of 2 quarters · filed 2020-02-25 | $2.92M derived: sum of 3 quarters · filed 2020-02-25 | $271.00K 10-K · filed 2021-02-11 |
| 2018-09-28 | -$7.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $1.10M derived: sum of 2 quarters · filed 2019-10-30 | -$1.55M 10-Q · filed 2019-10-30 | -$8.51M derived: sum of 4 quarters · filed 2020-02-25 |
| 2018-06-29 | $8.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $5.91M 10-Q · filed 2019-07-31 | -$1.05M derived: sum of 3 quarters · filed 2020-02-25 | |
| 2018-03-30 | -$2.65M 10-Q · filed 2019-05-01 | -$9.62M derived: sum of 2 quarters · filed 2020-02-25 | ||
| 2017-12-29 | -$6.96M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $13.74M 10-K · filed 2020-02-25 | ||
| 2017-09-29 | $20.71M 10-Q · filed 2018-11-01 | |||
| 2016-12-30 | $256.76M 10-K · filed 2019-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |